Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to leptomeningeal metastases (LM), a serious and often underdiagnosed complication of advanced cancer.

The updated NCCN CNS Cancers Guidelines reinforce that cerebrospinal fluid (CSF) analysis remains a standard component of LM diagnosis and disease assessment and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI and clinical evaluation.

CNSide is a CSF assay platform designed to support the diagnosis, treatment monitoring, and management of patients with LM and other metastatic central nervous system cancers. The Company believes the updated NCCN framework underscores the value of more sensitive and quantitative CSF-based tools that can operate within existing clinical workflows and complement standard CSF cytology over the course of a patient's treatment.